EN _ FR
BLOG
Reinforcement Learning with Expert Human Feedback (ReLEHF) to Advance Pharmaceutical Generative AI
New Milestone in AI Drug Discovery: First Generative AI Drug Begins Phase II Trials with Patients
Insilico Medicine is Using Generative AI to Design New Drugs for Rare Diseases
Insilico Medicine announces positive topline results of the New Zealand Phase 1 trial of INS018_055, an AI-designed drug for an AI-discovered target
Expanding the Immuno-oncology Toolbox with an AI-discovered Target and Novel Inhibitor
AI for Longevity and Prosperity: Prosperity7 Leads Insilico's $35 Million Round D2 for $95 Million Total Raise
Research Collaboration Using Insilico Medicine's AI Yields New Treatment Possibilities for ALS
Why I Left Big Pharma for AI: Insilico Medicine's Co-CEO Dr. Feng Ren
The next step in AI drug discovery: Robots
Using AI to Fight a Pandemic: Insilico Medicine Announces Novel Preclinical Candidate for COVID-19 Treatment
CB Insights Again Names Insilico Medicine One of the Top 100 AI Companies in the World
AI Accelerates Race for New Synthetic Lethality Therapeutics
Nominating Novel USP1 Small Molecule Inhibitor as a Preclinical Candidate for BRCA mutant tumors
Dual-purpose therapeutic targets predicted using AI
From Start to Phase 1 in 30 Months: AI-discovered and AI-designed Anti-fibrotic Drug Enters Phase I Clinical Trial
In under 40 days since announcing the partnership, Insilco Medicine and Fosun have selected preclinical candidate and initiated IND-enabling studies with an AI-discovered inhibitor of QPCTL target
Bridging Biology, Chemistry and Medicine in Drug Discovery and Development with End-to-End Artificial Intelligence: AI-discovered Novel Antifibrotic Drug Goes First-in-Human
Insilico Medicine Initiates First-in-Human Study of AI-discovered Drug
Insilico Medicine Announces the Preclinical Candidate for Kidney Fibrosis Discovered Using End-to-End Artificial Intelligence Engine
Insilico discovered a Novel disease mechanism, identified a Novel target, and designed a Novel molecule validated in preclinical experiments
Insilico Medicine to present Chemistry42 and the end-to-end drug discovery case study at NVIDIA GTC 2021
We are very happy to be presenting our approach to generative chemistry and the Chemistry42 platform at the NVIDIA GTC 2021 and the application of this platform which enabled the nomination of a pre-clinical candidate for a novel target for idiopathic pulmonary fibrosis (IPF) in under 18 months.
A breakthrough milestone in AI-powered drug discovery reached linking biology and chemistry with AI
AI-generated novel molecule for a novel target discovered with AI demonstrated efficacy in a broad therapeutic area and reached preclinical candidate stage in Idiopathic Pulmonary Fibrosis (IPF)